<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19624941</article-id>
      <article-id pub-id-type="pmc">2744244</article-id>
      <article-id pub-id-type="publisher-id">09-0024</article-id>
      <article-id pub-id-type="doi">10.3201/eid1507.090024</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Reactivation of Bovine Tuberculosis in Patient Treated with Infliximab, Switzerland</article-title>
        <alt-title alt-title-type="running-head">Reactivation of Bovine Tuberculosis in Patient Treated with Infliximab, Switzerland</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nager</surname>
            <given-names>Marina</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tarr</surname>
            <given-names>Philip E.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haack</surname>
            <given-names>Horst G.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martius</surname>
            <given-names>Ferdinand</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stoebe</surname>
            <given-names>Claudio</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frei</surname>
            <given-names>Reno</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Danuser</surname>
            <given-names>Juerg</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Jehle</surname>
            <given-names>Andreas W.</given-names>
          </name>
        </contrib>
        <aff id="aff1">University of Basel, Bruderholz, Switzerland (M. Nager, P.E. Tarr, H.G. Haack, F. Martius, C. Stoebe, A.W. Jehle)</aff>
        <aff id="aff2">University Hospital Basel, Basel, Switzerland (R. Frei)</aff>
        <aff id="aff3">Swiss Federal Veterinary Office, Berne, Switzerland (J. Danuser)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Andreas W. Jehle, Department of Medicine, Kantonsspital Bruderholz, University of Basel, CH-4101 Bruderholz, Switzerland; email: <email xlink:href="andreas.jehle@unibas.ch">andreas.jehle@unibas.ch</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2009</year>
      </pub-date>
      <volume>15</volume>
      <issue>7</issue>
      <fpage>1132</fpage>
      <lpage>1133</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Mycobacterium bovis</kwd>
        <kwd>bovine</kwd>
        <kwd>tuberculosis and other mycobacteria</kwd>
        <kwd>infliximab</kwd>
        <kwd>reactivation</kwd>
        <kwd>dairy products</kwd>
        <kwd>tumor necrosis factor</kwd>
        <kwd>Crohn&#x2019;s disease</kwd>
        <kwd>letter</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> Increased risk for reactivation of tuberculosis (TB) after treatment with tumor necrosis factor (TNF) antagonists, particularly infliximab, is well documented (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). We describe a case of peritoneal TB, probably resulting from reactivation of <italic>Mycobacterium bovis</italic> infection after infliximab treatment. In retrospect, reactivation might have been preventable had physicians been aware of the patient&#x2019;s history of regularly drinking fresh cow&#x2019;s milk from a local farm in Switzerland during 1944&#x2013;45, when bovine TB was prevalent.</p>
    <p>The patient was a 69-year-old Swiss woman who was examined for weakness, abdominal pain, increasing abdominal girth, and weight loss in April 2008. Her history included a diagnosis of Crohn disease in 1978 and treatment with glucocorticoids, cyclosporine, and mercaptopurine. In November 2007, during a recurrence of Crohn disease and while receiving treatment with azathioprine, the patient had a negative interferon gamma release assay (IGRA) result (QuantiFERON-TB in Tube test; Cellestis International, Carnegie, Victoria, Australia) and an unremarkable chest radiograph. On November 30, 2007, she was given prednisone (40 mg/d for 2 weeks, then tapered) and prescribed 3 doses of infliximab because of severe inflammation seen during colonoscopy (5 mg/kg on November 30, 2007, January 4, 2008, and February 15, 2008). She was hospitalized on April 25, 2008, at which time she had ascites; the fluid contained 1.4 &#xD7; 10<sup>9</sup>/L leukocytes (79.5% lymphocytes) but was negative for acid-fast bacilli on direct examination and PCR testing for <italic>Mycobacterium tuberculosis</italic> complex. Laparoscopy on May 2, 2008, showed extensive peritoneal inflammation. Peritoneal biopsy samples contained acid-fast bacilli and caseating granulomas; PCR for <italic>M. tuberculosis</italic> complex was positive. At this time, results of a repeat QuantiFERON-TB in Tube test and a tuberculin skin test (TST) were negative, but a T-SPOT.TB (Oxford Immunotec, Abingdon, UK) test was positive (6-kDa early secretory antigenic target [ESAT-6], &gt;20 spots; 10-kDa culture filtrate protein [CFP-10], 11 spots). <italic>M. bovis</italic> ssp. <italic>bovis</italic> was grown in cultures of peritoneal biopsy samples. For culture, the MGIT 960 automated culture system (Becton Dickinson, Sparks, MD, USA) was used. The isolate was identified by use of a multiplex PCR-based, solid-phase, reverse-hybridization assay (GenoType MTBC, Hain Lifescience GmbH, Nehren, Germany), excluding <italic>M. bovis</italic> BCG (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). The patient was discharged May 30, 2008. In January 2009, she was much improved after treatment with isoniazid/rifampin/ethambutol for 3 months and moxifloxacin/rifampin for 5 months.</p>
    <p>This case of presumed reactivation of peritoneal TB caused by <italic>M. bovis</italic> in a patient treated with infliximab highlights the need to be aware of local epidemiology with regard to transmissible infectious diseases. It particularly emphasizes the value of careful history taking regarding consumption of unpasteurized dairy products in assessing risk for latent TB infection (LTBI) before starting anti-TNF treatment. Some infectious diseases experts (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>) recommend considering LTBI treatment before prescribing anti-TNF therapy even when TST is negative or only minimally positive (&lt;5 mm induration) for patients with epidemiologic or clinical hints of LTBI. This case indicates that this recommendation should be extended to assessment of the probability of latent <italic>M. bovis</italic> infection. This decision may not be easy, and referral to a TB specialist should be considered. Excluding LTBI on the basis of a negative TST result or IGRA is problematic because of the limited sensitivity of these tests, especially for immunosuppressed patients (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Of note, the antigens used in IGRAs are present in <italic>M. bovis</italic>. Discordant TST and IGRA results are frequent, and these differences are not easily explained (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). However, IGRAs are not confounded by prior vaccination with <italic>M. bovis</italic> BCG, and the T-SPOT.TB test may have a higher sensitivity than QuantiFERON-TB and QuantiFERON-TB Gold tests (Cellestis International) (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). Our patient had a positive T-SPOT.TB result and negative QuantiFERON-TB and TST results at the time of her diagnosis of peritoneal TB.</p>
    <p>Recently, another case of peritoneal TB due to <italic>M. bovis</italic> in a patient treated with infliximab was reported in Denmark. This patient&#x2019;s exposure presumably consisted of consumption of unpasteurized milk at a dairy (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). Tuberculosis cases caused by <italic>M. bovis</italic> are probably underreported because many laboratories determine only whether a pathogen belongs to <italic>M. tuberculosis</italic> complex. In the United States, genotyping of culture-confirmed <italic>M. tuberculosis</italic> complex has been routinely done only since 2004 (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>).</p>
    <p>Our patient probably acquired <italic>M. bovis</italic> infection by frequent consumption of unpasteurized milk in a rural area of Switzerland during the 1940s. Infection by the respiratory route is conceivable but unlikely. As the patient traveled rarely, and only in industrialized countries, more recent transmission of <italic>M. bovis</italic> seems unlikely. According to the requirements of section 3.2.3.10 of the World Organisation for Animal Health International Animal Health Code, Switzerland has officially been free from bovine TB since 1959. The last sporadic case occurred in 2003, although eradication has not been achieved in all neighboring European countries (<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>). Of note, in the United States and Canada, where <italic>M. bovis</italic> has been virtually eliminated in cattle (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>), <italic>M. bovis</italic> infection continues to be diagnosed today, particularly in children of Hispanic origin and those born outside the United States. The principal infection route may be consumption of unpasteurized dairy products from Mexico (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>). Awareness of the epidemiology of bovine TB and careful history taking regarding recent or distant (in countries where <italic>M. bovis</italic> infection in cattle has been eradicated) consumption of unpasteurized dairy products may prompt preventive chemotherapy before the start of anti-TNF treatment. Thus, a potentially increasing number of human TB cases due to <italic>M. bovis</italic> may be prevented<italic>.</italic></p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Nager M, Tarr PE, Haack HG, Martius F, Stoebe C, Frei R, et al. Reactivation of bovine tuberculosis in patient treated with infliximab, Switzerland [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Jul [<italic>date cited</italic>]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/EID/content/15/7/1132.htm">http://www.cdc.gov/EID/content/15/7/1132.htm</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Wallis</surname> <given-names>RS</given-names></string-name> <article-title>Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.</article-title><source>Lancet Infect Dis</source> <year>2008</year>;<volume>8</volume>:<fpage>601</fpage>&#x2013;<lpage>11</lpage> <pub-id pub-id-type="doi">10.1016/S1473-3099(08)70227-5</pub-id><pub-id pub-id-type="pmid">18922482</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Somoskovi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dormandy</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rivenburg</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pedrosa</surname> <given-names>M</given-names></string-name>, <string-name><surname>McBride</surname> <given-names>M</given-names></string-name>, <string-name><surname>Salfinger</surname> <given-names>M</given-names></string-name> <article-title>Direct comparison of the genotype MTBC and genomic deletion assays in terms of ability to distinguish between members of the <italic>Mycobacterium tuberculosis</italic> complex in clinical isolates and in clinical specimens.</article-title><source>J Clin Microbiol</source> <year>2008</year>;<volume>46</volume>:<fpage>1854</fpage>&#x2013;<lpage>7</lpage> <pub-id pub-id-type="doi">10.1128/JCM.00105-07</pub-id><pub-id pub-id-type="pmid">18353933</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><collab>Centers for Disease Control and Prevention</collab> <article-title>Tuberculosis associated with blocking agents against tumor necrosis factor-alpha&#x2014;California, 2002&#x2013;2003.</article-title><source>MMWR Morb Mortal Wkly Rep</source> <year>2004</year>;<volume>53</volume>:<fpage>683</fpage>&#x2013;<lpage>6</lpage><pub-id pub-id-type="pmid">15295313</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Menzies</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pai</surname> <given-names>M</given-names></string-name>, <string-name><surname>Comstock</surname> <given-names>G</given-names></string-name> <article-title>Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.</article-title><source>Ann Intern Med</source> <year>2007</year>;<volume>146</volume>:<fpage>340</fpage>&#x2013;<lpage>54</lpage><pub-id pub-id-type="pmid">17339619</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Lalvani</surname> <given-names>A</given-names></string-name> <article-title>Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy.</article-title><source>Chest</source> <year>2007</year>;<volume>131</volume>:<fpage>1898</fpage>&#x2013;<lpage>906</lpage> <pub-id pub-id-type="doi">10.1378/chest.06-2471</pub-id><pub-id pub-id-type="pmid">17565023</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Pai</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zwerling</surname> <given-names>A</given-names></string-name>, <string-name><surname>Menzies</surname> <given-names>D</given-names></string-name> <article-title>Systematic review: T-cell&#x2013;based assays for the diagnosis of latent tuberculosis infection: an update.</article-title><source>Ann Intern Med</source> <year>2008</year>;<volume>149</volume>:<fpage>177</fpage>&#x2013;<lpage>84</lpage><pub-id pub-id-type="pmid">18593687</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Larsen</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Sorensen</surname> <given-names>IJ</given-names></string-name>, <string-name><surname>Thomsen</surname> <given-names>VO</given-names></string-name>, <string-name><surname>Ravn</surname> <given-names>P</given-names></string-name> <article-title>Re-activation of bovine tuberculosis in a patient treated with infliximab.</article-title><source>Eur Respir J</source> <year>2008</year>;<volume>32</volume>:<fpage>229</fpage>&#x2013;<lpage>31</lpage> <pub-id pub-id-type="doi">10.1183/09031936.00125607</pub-id><pub-id pub-id-type="pmid">18591340</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Hlavsa</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Moonan</surname> <given-names>PK</given-names></string-name>, <string-name><surname>Cowan</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Navin</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Kammerer</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Morlock</surname> <given-names>GP</given-names></string-name>, <etal/><article-title>Human tuberculosis due to <italic>Mycobacterium bovis</italic> in the United States, 1995&#x2013;2005.</article-title><source>Clin Infect Dis</source> <year>2008</year>;<volume>47</volume>:<fpage>168</fpage>&#x2013;<lpage>75</lpage> <pub-id pub-id-type="doi">10.1086/589240</pub-id><pub-id pub-id-type="pmid">18532886</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Reviriego Gordejo</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Vermeersch</surname> <given-names>JP</given-names></string-name> <article-title>Towards eradication of bovine tuberculosis in the European Union.</article-title><source>Vet Microbiol</source> <year>2006</year>;<volume>112</volume>:<fpage>101</fpage>&#x2013;<lpage>9</lpage> <pub-id pub-id-type="doi">10.1016/j.vetmic.2005.11.034</pub-id><pub-id pub-id-type="pmid">16388921</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="book"><string-name><surname>Gilsdorf</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Ebel</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Disney</surname> <given-names>TW</given-names></string-name> Benefit and cost assessment of the U.S. bovine tuberculosis eradication program. In: Thoen CO, Steele JH, Gilsdorf MJ, editors. <italic>Mycobacterium bovis</italic> infections in animals and humans. 2nd ed. Ames (IA): Blackwell Publishing; <year>2006</year> p. 89&#x2013;99.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
